Compare BIO-TECHNE Corp (TECH) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Under Armour Inc Class A — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Under Armour Inc Class A trades at $4.74 (market cap $2.05B). The key difference: BIO-TECHNE Corp is far larger — about 5.5× Under Armour Inc Class A's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Under Armour Inc Class A for 18 Days on average.
| TECH | UA | |
|---|---|---|
Market Cap | $11.37B | $2.05B |
Volume | 3,153,511 | 3,002,780 |
Sector | Health | Consumer Cyclical |
52-Week High | $72.61 | $7.88 |
52-Week Low | $43.31 | $3.96 |
Typical Hold Time | 63 Days | 18 Days |
Enterprise Value | $11.40B | $3.03B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Under Armour (UA) trades at $4.70, down 0.42% with a bearish technical outlook despite recent earnings beats. The company faces significant challenges with negative net income margins (-9.99%) and declining revenue trends, though it maintains a reasonable P/S ratio of 0.41. Recent quarterly results show mixed performance with two beats and one miss, while cash flow remains negative across all categories.
The stock presents high risk with deteriorating fundamentals and negative profitability metrics. While analyst sentiment leans slightly positive with 41% buy ratings, the company's revenue declines and negative cash flow position create substantial headwinds. Investment opportunity exists only for those betting on a successful turnaround strategy execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
